調査レポート | • レポートコード：QYR2104Z0372 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア |
| Single User | ￥553,800 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥830,700 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,107,600 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、抗体薬物複合体（ADC）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（シアトルジェネティクス技術、イミュノゲン技術、イミュノメディクス技術）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・抗体薬物複合体（ADC）の市場動向 ・企業の競争状況、市場シェア ・抗体薬物複合体（ADC）の種類別市場規模（シアトルジェネティクス技術、イミュノゲン技術、イミュノメディクス技術） ・抗体薬物複合体（ADC）の用途別市場規模（病院、クリニック、その他） ・抗体薬物複合体（ADC）の北米市場規模2016-2027（アメリカ、カナダ） ・抗体薬物複合体（ADC）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・抗体薬物複合体（ADC）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・抗体薬物複合体（ADC）の中南米市場規模2016-2027（メキシコ、ブラジル） ・抗体薬物複合体（ADC）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Roche、Pfizer、Novartis、Genmab、Bayer、Seattle Genetics、Takeda Pharmaceuticals、AbbVie、AbGenomics、ADC Therapeutics、Astellas Pharma、Kairos Therapeutics） ・結論 |
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue. ADCs are part of a specialized subset of highly potent APIs. This technically challenging type of therapy combines innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs.
Advances in coupling antibodies to cytotoxic drugs permit greater control of drug pharmacokinetics and significantly improve delivery to target tissue. Potent new anti-cancer drugs can now be used to target cancers while minimizing exposure of healthy tissue.
Market Analysis and Insights: Global Antibody Drug Conjugates (ADCs) Market
The global Antibody Drug Conjugates (ADCs) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antibody Drug Conjugates (ADCs) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antibody Drug Conjugates (ADCs) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antibody Drug Conjugates (ADCs) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antibody Drug Conjugates (ADCs) market.
Global Antibody Drug Conjugates (ADCs) Scope and Market Size
Antibody Drug Conjugates (ADCs) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antibody Drug Conjugates (ADCs) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Seattle Genetics Technology
ImmunoGen Technology
Immunomedics Technology
Segment by Application
Hospital
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Roche
Pfizer
Novartis
Genmab
Bayer
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
Genmab
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Seattle Genetics Technology
1.2.3 ImmunoGen Technology
1.2.4 Immunomedics Technology
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugates (ADCs) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Antibody Drug Conjugates (ADCs) Market Perspective (2016-2027)
2.2 Antibody Drug Conjugates (ADCs) Growth Trends by Regions
2.2.1 Antibody Drug Conjugates (ADCs) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Antibody Drug Conjugates (ADCs) Historic Market Share by Regions (2016-2021)
2.2.3 Antibody Drug Conjugates (ADCs) Forecasted Market Size by Regions (2022-2027)
2.3 Antibody Drug Conjugates (ADCs) Industry Dynamic
2.3.1 Antibody Drug Conjugates (ADCs) Market Trends
2.3.2 Antibody Drug Conjugates (ADCs) Market Drivers
2.3.3 Antibody Drug Conjugates (ADCs) Market Challenges
2.3.4 Antibody Drug Conjugates (ADCs) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugates (ADCs) Players by Revenue
3.1.1 Global Top Antibody Drug Conjugates (ADCs) Players by Revenue (2016-2021)
3.1.2 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Players (2016-2021)
3.2 Global Antibody Drug Conjugates (ADCs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Antibody Drug Conjugates (ADCs) Revenue
3.4 Global Antibody Drug Conjugates (ADCs) Market Concentration Ratio
3.4.1 Global Antibody Drug Conjugates (ADCs) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugates (ADCs) Revenue in 2020
3.5 Antibody Drug Conjugates (ADCs) Key Players Head office and Area Served
3.6 Key Players Antibody Drug Conjugates (ADCs) Product Solution and Service
3.7 Date of Enter into Antibody Drug Conjugates (ADCs) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody Drug Conjugates (ADCs) Breakdown Data by Type
4.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Type (2016-2021)
4.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Type (2022-2027)
5 Antibody Drug Conjugates (ADCs) Breakdown Data by Application
5.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Application (2016-2021)
5.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Antibody Drug Conjugates (ADCs) Market Size (2016-2027)
6.2 North America Antibody Drug Conjugates (ADCs) Market Size by Type
6.2.1 North America Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021)
6.2.2 North America Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027)
6.2.3 North America Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2027)
6.3 North America Antibody Drug Conjugates (ADCs) Market Size by Application
6.3.1 North America Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021)
6.3.2 North America Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027)
6.3.3 North America Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2027)
6.4 North America Antibody Drug Conjugates (ADCs) Market Size by Country
6.4.1 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021)
6.4.2 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Antibody Drug Conjugates (ADCs) Market Size (2016-2027)
7.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Type
7.2.1 Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021)
7.2.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027)
7.2.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2027)
7.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Application
7.3.1 Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021)
7.3.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027)
7.3.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2027)
7.4 Europe Antibody Drug Conjugates (ADCs) Market Size by Country
7.4.1 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021)
7.4.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size (2016-2027)
8.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Type
8.2.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2027)
8.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Application
8.3.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2027)
8.4 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region
8.4.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Antibody Drug Conjugates (ADCs) Market Size (2016-2027)
9.2 Latin America Antibody Drug Conjugates (ADCs) Market Size by Type
9.2.1 Latin America Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021)
9.2.2 Latin America Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027)
9.2.3 Latin America Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2027)
9.3 Latin America Antibody Drug Conjugates (ADCs) Market Size by Application
9.3.1 Latin America Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021)
9.3.2 Latin America Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027)
9.3.3 Latin America Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2027)
9.4 Latin America Antibody Drug Conjugates (ADCs) Market Size by Country
9.4.1 Latin America Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021)
9.4.2 Latin America Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size (2016-2027)
10.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type
10.2.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2027)
10.3 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application
10.3.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2027)
10.4 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country
10.4.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Antibody Drug Conjugates (ADCs) Introduction
11.1.4 Roche Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Antibody Drug Conjugates (ADCs) Introduction
11.2.4 Pfizer Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Antibody Drug Conjugates (ADCs) Introduction
11.3.4 Novartis Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
11.3.5 Novartis Recent Development
11.4 Genmab
11.4.1 Genmab Company Details
11.4.2 Genmab Business Overview
11.4.3 Genmab Antibody Drug Conjugates (ADCs) Introduction
11.4.4 Genmab Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
11.4.5 Genmab Recent Development
11.5 Bayer
11.5.1 Bayer Company Details
11.5.2 Bayer Business Overview
11.5.3 Bayer Antibody Drug Conjugates (ADCs) Introduction
11.5.4 Bayer Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
11.5.5 Bayer Recent Development
11.6 Seattle Genetics
11.6.1 Seattle Genetics Company Details
11.6.2 Seattle Genetics Business Overview
11.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Introduction
11.6.4 Seattle Genetics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
11.6.5 Seattle Genetics Recent Development
11.7 Takeda Pharmaceuticals
11.7.1 Takeda Pharmaceuticals Company Details
11.7.2 Takeda Pharmaceuticals Business Overview
11.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Introduction
11.7.4 Takeda Pharmaceuticals Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
11.7.5 Takeda Pharmaceuticals Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Antibody Drug Conjugates (ADCs) Introduction
11.8.4 AbbVie Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
11.8.5 AbbVie Recent Development
11.9 AbGenomics
11.9.1 AbGenomics Company Details
11.9.2 AbGenomics Business Overview
11.9.3 AbGenomics Antibody Drug Conjugates (ADCs) Introduction
11.9.4 AbGenomics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
11.9.5 AbGenomics Recent Development
11.10 ADC Therapeutics
11.10.1 ADC Therapeutics Company Details
11.10.2 ADC Therapeutics Business Overview
11.10.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Introduction
11.10.4 ADC Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
11.10.5 ADC Therapeutics Recent Development
11.11 Astellas Pharma
11.11.1 Astellas Pharma Company Details
11.11.2 Astellas Pharma Business Overview
11.11.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Introduction
11.11.4 Astellas Pharma Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
11.11.5 Astellas Pharma Recent Development
11.12 Kairos Therapeutics
11.12.1 Kairos Therapeutics Company Details
11.12.2 Kairos Therapeutics Business Overview
11.12.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Introduction
11.12.4 Kairos Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021)
11.12.5 Kairos Therapeutics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Seattle Genetics Technology
Table 3. Key Players of ImmunoGen Technology
Table 4. Key Players of Immunomedics Technology
Table 5. Global Antibody Drug Conjugates (ADCs) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Antibody Drug Conjugates (ADCs) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Antibody Drug Conjugates (ADCs) Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Antibody Drug Conjugates (ADCs) Market Share by Regions (2016-2021)
Table 9. Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Antibody Drug Conjugates (ADCs) Market Share by Regions (2022-2027)
Table 11. Antibody Drug Conjugates (ADCs) Market Trends
Table 12. Antibody Drug Conjugates (ADCs) Market Drivers
Table 13. Antibody Drug Conjugates (ADCs) Market Challenges
Table 14. Antibody Drug Conjugates (ADCs) Market Restraints
Table 15. Global Antibody Drug Conjugates (ADCs) Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Antibody Drug Conjugates (ADCs) Market Share by Players (2016-2021)
Table 17. Global Top Antibody Drug Conjugates (ADCs) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibody Drug Conjugates (ADCs) as of 2020)
Table 18. Ranking of Global Top Antibody Drug Conjugates (ADCs) Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Antibody Drug Conjugates (ADCs) Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Antibody Drug Conjugates (ADCs) Product Solution and Service
Table 22. Date of Enter into Antibody Drug Conjugates (ADCs) Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2016-2021)
Table 26. Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Antibody Drug Conjugates (ADCs) Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2016-2021)
Table 30. Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2022-2027) & (US$ Million)
Table 62. Roche Company Details
Table 63. Roche Business Overview
Table 64. Roche Antibody Drug Conjugates (ADCs) Product
Table 65. Roche Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
Table 66. Roche Recent Development
Table 67. Pfizer Company Details
Table 68. Pfizer Business Overview
Table 69. Pfizer Antibody Drug Conjugates (ADCs) Product
Table 70. Pfizer Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Novartis Company Details
Table 73. Novartis Business Overview
Table 74. Novartis Antibody Drug Conjugates (ADCs) Product
Table 75. Novartis Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
Table 76. Novartis Recent Development
Table 77. Genmab Company Details
Table 78. Genmab Business Overview
Table 79. Genmab Antibody Drug Conjugates (ADCs) Product
Table 80. Genmab Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
Table 81. Genmab Recent Development
Table 82. Bayer Company Details
Table 83. Bayer Business Overview
Table 84. Bayer Antibody Drug Conjugates (ADCs) Product
Table 85. Bayer Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
Table 86. Bayer Recent Development
Table 87. Seattle Genetics Company Details
Table 88. Seattle Genetics Business Overview
Table 89. Seattle Genetics Antibody Drug Conjugates (ADCs) Product
Table 90. Seattle Genetics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
Table 91. Seattle Genetics Recent Development
Table 92. Takeda Pharmaceuticals Company Details
Table 93. Takeda Pharmaceuticals Business Overview
Table 94. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product
Table 95. Takeda Pharmaceuticals Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
Table 96. Takeda Pharmaceuticals Recent Development
Table 97. AbbVie Company Details
Table 98. AbbVie Business Overview
Table 99. AbbVie Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
Table 100. AbbVie Recent Development
Table 101. AbGenomics Company Details
Table 102. AbGenomics Business Overview
Table 103. AbGenomics Antibody Drug Conjugates (ADCs) Product
Table 104. AbGenomics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
Table 105. AbGenomics Recent Development
Table 106. ADC Therapeutics Company Details
Table 107. ADC Therapeutics Business Overview
Table 108. ADC Therapeutics Antibody Drug Conjugates (ADCs) Product
Table 109. ADC Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
Table 110. ADC Therapeutics Recent Development
Table 111. Astellas Pharma Company Details
Table 112. Astellas Pharma Business Overview
Table 113. Astellas Pharma Antibody Drug Conjugates (ADCs) Product
Table 114. Astellas Pharma Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
Table 115. Astellas Pharma Recent Development
Table 116. Kairos Therapeutics Company Details
Table 117. Kairos Therapeutics Business Overview
Table 118. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product
Table 119. Kairos Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2016-2021) & (US$ Million)
Table 120. Kairos Therapeutics Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antibody Drug Conjugates (ADCs) Market Share by Type: 2020 VS 2027
Figure 2. Seattle Genetics Technology Features
Figure 3. ImmunoGen Technology Features
Figure 4. Immunomedics Technology Features
Figure 5. Global Antibody Drug Conjugates (ADCs) Market Share by Application: 2020 VS 2027
Figure 6. Hospital Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Antibody Drug Conjugates (ADCs) Report Years Considered
Figure 10. Global Antibody Drug Conjugates (ADCs) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Antibody Drug Conjugates (ADCs) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Antibody Drug Conjugates (ADCs) Market Share by Regions: 2020 VS 2027
Figure 13. Global Antibody Drug Conjugates (ADCs) Market Share by Regions (2022-2027)
Figure 14. Global Antibody Drug Conjugates (ADCs) Market Share by Players in 2020
Figure 15. Global Top Antibody Drug Conjugates (ADCs) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibody Drug Conjugates (ADCs) as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Antibody Drug Conjugates (ADCs) Revenue in 2020
Figure 17. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2016-2021)
Figure 18. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2022-2027)
Figure 19. North America Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Antibody Drug Conjugates (ADCs) Market Share by Type (2016-2027)
Figure 21. North America Antibody Drug Conjugates (ADCs) Market Share by Application (2016-2027)
Figure 22. North America Antibody Drug Conjugates (ADCs) Market Share by Country (2016-2027)
Figure 23. United States Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Antibody Drug Conjugates (ADCs) Market Share by Type (2016-2027)
Figure 27. Europe Antibody Drug Conjugates (ADCs) Market Share by Application (2016-2027)
Figure 28. Europe Antibody Drug Conjugates (ADCs) Market Share by Country (2016-2027)
Figure 29. Germany Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Antibody Drug Conjugates (ADCs) Market Share by Region (2016-2027)
Figure 39. China Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Antibody Drug Conjugates (ADCs) Market Share by Type (2016-2027)
Figure 47. Latin America Antibody Drug Conjugates (ADCs) Market Share by Application (2016-2027)
Figure 48. Latin America Antibody Drug Conjugates (ADCs) Market Share by Country (2016-2027)
Figure 49. Mexico Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Antibody Drug Conjugates (ADCs) Market Share by Country (2016-2027)
Figure 55. Turkey Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Antibody Drug Conjugates (ADCs) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Roche Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
Figure 59. Pfizer Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
Figure 60. Novartis Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
Figure 61. Genmab Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
Figure 62. Bayer Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
Figure 63. Seattle Genetics Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
Figure 64. Takeda Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
Figure 65. AbbVie Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
Figure 66. AbGenomics Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
Figure 67. ADC Therapeutics Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
Figure 68. Astellas Pharma Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
Figure 69. Kairos Therapeutics Revenue Growth Rate in Antibody Drug Conjugates (ADCs) Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
世界の抗体薬物複合体（ADC）薬物市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Antibody Drug Conjugate (ADC) Drug Market The global Antibody Drug Conjugate (ADC) Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high …- 世界の抗体薬物複合体（ADC）治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Antibody Drug Conjugate Therapeutics Market The global Antibody Drug Conjugate Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and h…
- 世界の抗体薬物複合体市場 2021：企業別、地域別、種類・用途別 The Antibody Drug Conjugate market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…
- 世界のヒト化抗体市場規模・現状・予測（2021年-2027年） Humanized antibodies mainly refer to antibodies re-expressed by gene cloning and DNA recombination technology of mouse monoclonal antibodies, most of the amino acid sequences of which are replaced by human sequences, and reducing the Its heterogeneity is beneficial to the human body.The constant reg…
- 世界の併用抗体療法市場規模・現状・予測（2021年-2027年） Combination antibody therapy is receiving higher recognition from the oncological branch of medical science research. This is primarily due to the growing use of combination therapy over single drug treatments such as radiation or chemotherapy. In addition, companies that manufacture combination ant…